Why VHH needs a format-specific screen
Single-domain antibodies (VHHs or nanobodies) are compact antigen-binding domains rather than full-length IgG molecules. Their small size can be advantageous, but neither predicted folding confidence nor computational docking establishes practical expression yield, solubility or long-term stability. Exposed surface patches, sequence-specific hydrophobicity, disulfide behavior and the selected expression host can all affect a VHH program.
Start by defining the intended research format. A standalone VHH, VHH-Fc fusion and multivalent construct are not interchangeable: Fc fusion changes molecular size, valency, Fc-related biology and analytical expectations. Establish whether the relevant decision is biochemical binding, cell engagement or production of material for a study.
A minimum VHH wet-lab evidence set
| Question | Early experiment | Decision signal |
|---|---|---|
| Can it be produced? | Small-scale expression and purification | Recovered soluble product, not crude expression alone |
| Is the sample predominantly monomeric? | SEC with relevant controls; orthogonal method when needed | Monomer / high-molecular-weight fractions and peak shape |
| Is it folded and reasonably stable? | nanoDSF or another suitable thermal method | Interpretable unfolding profile, onset, and aggregation behavior |
| Does it engage the intended antigen? | SPR, BLI or suitable functional assay | Reproducible binding with appropriate negative controls |
| Will it remain usable? | Short, decision-relevant hold or handling challenge | Recovery, appearance, monomer and retained activity |
These are screening measurements rather than a universal release specification. Assay selection and acceptance criteria depend on sample availability and intended use.
Interpreting apparently strong candidates
A candidate may bind tightly and still be a poor starting material because purified recovery is low or soluble aggregates dominate. Conversely, a weaker binder with reproducible expression and cleaner analytics may justify optimization. Use like-for-like production and test conditions when comparing a sequence panel; differences in host, purification or concentration can overwhelm sequence-related effects.
Thermal unfolding temperature is useful but not a stand-alone shelf-life predictor. A high transition temperature does not prove favorable colloidal stability, and low-concentration results do not automatically predict performance at the concentration needed for dosing. SEC may miss insoluble particles, and a monomer fraction alone says little about biological potency.
Controls worth specifying in the CRO brief
- Sequence version, construct boundaries, tag placement, theoretical molecular weight and intended format.
- Host system and a consistent expression/purification workflow across candidates.
- Protein concentration method, sample buffer, storage and freeze-thaw history.
- SEC chromatograms, integration approach and recovery; replicate data where feasible.
- Target quality, reference binding controls and a specificity check when relevant.
- Evidence-based recommendation: advance, optimize, or retest—with uncertainties explicit.
For a mixed VHH and IgG panel, use format-aware comparisons rather than applying the same absolute thresholds indiscriminately.
From assay panel to candidate decision
An efficient sequence-to-preclinical funnel first screens feasibility and soluble recovery, then confirms monomeric material and credible target engagement, followed by targeted stress or stability work for shortlisted candidates. This staged approach limits the amount of material consumed by lower-confidence designs.
Explore the broader antibody developability decision framework, expression and purification considerations, and research-use assay menu.
Scientific context
- Improving the production and stability of nanobodies (2025)
- Developability assessment at early-stage discovery (2023)
Background reading; links do not imply endorsement or a service partnership.